{
    "clinical_study": {
        "@rank": "6589", 
        "acronym": "ROBI", 
        "arm_group": [
            {
                "arm_group_label": "EE 30mcg/LNG 150mcg", 
                "arm_group_type": "Active Comparator", 
                "description": "combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This double-blinded, placebo-controlled, randomized trial will compare the effects of the\n      use of a combined oral contraceptive pill to a placebo pill for women who are experiencing\n      irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant.\n\n      The hypothesis of the study is:\n\n        -  Use of combined oral contraceptive will significantly improve bleeding patterns for\n           users of ETG implant\n\n        -  Continuation rate of ETG implant users will be increased by use of combined oral\n           contraceptive in women desiring ETG implant removal because of the undesirable bleeding\n\n        -  Adverse events will be uncommon and acceptable to women who use a combined oral\n           contraceptive with the ETG implant"
        }, 
        "brief_title": "Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Abnormal Uterine Bleeding, Unspecified", 
            "Uterine Bleeding Heavy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Uterine Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Women who are experiencing irregular and/or heavy bleeding associated with the use of an\n      etonogestrel (ETG) implant will be recruited for this study.  Women who have bothersome\n      bleeding will be randomized to use either a combined oral contraceptive pill or a placebo\n      pill.\n\n      Participants will take one pill every day and record their bleeding patterns on a daily\n      diary.\n\n      Participants will have one screening/enrollment visit, two in-person follow up visits, and\n      one telephone follow up contact.  Subjects will be enrolled for a total of 84 days (three\n      months).\n\n      Participants will be assigned to a treatment group at her screening/enrollment visit.  Her\n      first follow up visit will occur 22-28 days after her enrollment.  Participants can choose\n      to:\n\n        -  Continue use of assigned treatment medication\n\n        -  Discontinue use of assigned treatment medication, but use an open-label combined oral\n           contraceptive pill\n\n        -  Discontinue the use of assigned treatment medication, decline use of an open-label\n           combined oral contraceptive pill\n\n        -  Discontinue use of ETG implant.\n\n      Participants who choose to continue use of ETG implant will have a follow up telephone\n      contact 50-56 days after her enrollment visit.  A final in-person visit will occur 78-84\n      days after enrollment.  Bleeding patterns will be assessed by daily bleeding diaries\n      completed by the participant."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women who have an ETG implant in place\n\n          -  Women who subjectively experience the side effect of an undesirable bleeding profile\n             such as bleeding irregularity or heavy flow after ETG implant was placed and who\n             desire intervention for this side effect by either treatment of bleeding or removal\n             of the implant\n\n          -  Age 14 years an older, inclusive\n\n        Exclusion Criteria:\n\n          -  Irregular or heavy bleeding from an etiology other than ETG use (e.g. fibroids,\n             cervical polyp, or other organic cause of bleeding)\n\n          -  Has attempted prescription treatment for menstrual side effects while using ETG\n             implant\n\n          -  Has one or more of the conditions considered Category 3 (risks outweigh benefits) or\n             Category 4 (unacceptable health risk) for estrogen-containing oral contraceptives by\n             the Center for Disease Control Medical Eligibility Criteria for Contraceptive Use:\n\n               -  Current or history of heart or vascular diseases, including deep venous\n                  thrombosis, pulmonary embolism, known thrombogenic mutations, peripartum\n                  cardiomyopathy, and complicated valvular heart disease\n\n               -  Hypertension, even if adequately controlled\n\n               -  Diabetes with vascular involvement\n\n               -  Headaches with focal aura, or migraines in women age 35 and older even without\n                  focal aura\n\n               -  Major surgery with prolonged immobilization\n\n               -  Breast cancer (current or past)\n\n               -  Severe (decompensated) cirrhosis\n\n               -  Acute or flare viral hepatitis\n\n               -  Breastfeeding less than 1 month postpartum\n\n               -  Post-partum less than 3 weeks\n\n               -  35 years of age and older and smoking\n\n               -  Multiple risk factors for arterial cardiovascular disease\n\n               -  Systemic Lupus Erythematosus with positive or unknown antiphospholipid\n                  antibodies\n\n               -  Current symptomatic gallbladder disease or history of cholestasis related to\n                  past combined oral contraceptive use\n\n               -  On certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone,\n                  topiramate, oxcarbazepine, lamotrigine)\n\n               -  On Ritonavir-boosted protease inhibitors for antiretroviral therapy\n\n          -  Issues or concerns, in the judgment of the investigator, that may compromise the\n             safety of the subject, impact the subject's adherence to the protocol requirements,\n             or confound the reliability of the data acquired in this study"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "14 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01963403", 
            "org_study_id": "UCD IRB Protocol Number 478388", 
            "secondary_id": "MISP 50618"
        }, 
        "intervention": [
            {
                "arm_group_label": "EE 30mcg/LNG 150mcg", 
                "description": "1 pill per day; daily during study participation (up to 84 days)", 
                "intervention_name": "EE 30mcg/LNG 150mcg", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Levlen28", 
                    "Levora", 
                    "Portia 28", 
                    "Altavera"
                ]
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Contraceptive Agents", 
                "Contraceptives, Oral", 
                "Contraceptives, Oral, Combined"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "etonogestrel implant", 
            "birth control", 
            "irregular bleeding", 
            "heavy bleeding"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": [
            {
                "contact": {
                    "email": "sarah.steimer@ucdmc.ucdavis.edu", 
                    "last_name": "Sarah Steimer", 
                    "phone": "916-734-6886"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California, Davis Department of Obstetrics and Gynecology"
                }, 
                "investigator": {
                    "last_name": "Mitchell Creinin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maddipatir@wudosis.wustl.edu", 
                    "last_name": "Ragini Maddipati, MSW", 
                    "phone": "314-747-6418"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School of Medicine, Department of Obstetrics and Gynecology"
                }, 
                "investigator": {
                    "last_name": "Colleen McNicholas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Relief of Bleeding on the Implant: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With a Combined Oral Contraceptive: A Placebo-Controlled Randomized Trial", 
        "other_outcome": [
            {
                "description": "Treatment success will be measured by desire to continue treatment because the initial treatment made the bleeding better.\nPartial failure of the study treatment will be measured by the desire to continue treatment because the initial treatment did not work\nComplete failure of treatment will be measured by the desire to:\ndiscontinue treatment because it did not work; no further treatment requested\nETG implant removal\nDesire to use non-study treatment", 
                "measure": "Treatment Success or Failure", 
                "safety_issue": "No", 
                "time_frame": "Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months"
            }, 
            {
                "description": "Bleeding improvement in women who received placebo but opted for open-label treatment after first cycle\nBleeding improvement over the 84 days of study participation\nBleeding patterns in placebo vs. combined oral contraceptive users", 
                "measure": "Bleeding patterns", 
                "safety_issue": "No", 
                "time_frame": "Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months"
            }
        ], 
        "overall_contact": {
            "email": "sarah.steimer@ucdmc.ucdavis.edu", 
            "last_name": "Sarah Steimer", 
            "phone": "916-734-6846"
        }, 
        "overall_official": [
            {
                "affiliation": "University of California, Davis", 
                "last_name": "Mitchell Creinin, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University of California, Davis", 
                "last_name": "Melody Hou, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Bleeding improvement will be measured by participant response to the question of whether she feels her bleeding is improved and she is satisfied with the treatment.", 
            "measure": "Bleeding Improvement", 
            "safety_issue": "No", 
            "time_frame": "Bleeding improvement will be evaluated during first cycle of study treatment (28 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01963403"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of California, Davis", 
            "investigator_full_name": "Mitchell Creinin, MD", 
            "investigator_title": "Professor and Department Chair", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Participants will be evaluated for adverse events while using a combined oral contraceptive with ETG implant.", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Adverse events will be evaluated at each contact (visits at 1 and 3 months, phone contact at 2 months) with the participant"
        }, 
        "source": "University of California, Davis", 
        "sponsors": {
            "collaborator": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of California, Davis", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}